Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Inclusion Criteria: * Histologically verified adenocarcinoma arisen from gallbladder, extra or intrahepatic bile ducts or malignant cells consistent with the above and concomitant radiologic findings consistent with cholangiocarcinoma. * Curative treatment presently discounted (surgery, stereotactic radiotherapy, etc.) * KRAS analyzed and found wild-type (wt) or mutated * PS 0-2 * Evaluable disease according to RECIST criteria, i.e., the disease does not need to be measurable * Haematology: * ANC ≥ 1.5 x 10\^9/l * Thrombocytes ≥ 100x10\^9/l * Biochemistry: * Bilirubinaemia ≤ 3 x upper normal value * ALAT ≤ 5 x upper normal value * Creatinin ≤ upper normal value. If raised creatinin, the measured or calculated GFR must be at least 50% of the lower normal value. * Fertile women must present a negative pregnancy test and use birth control during and 3 months after treatment. The following methods are considered safe birth control: Birth control pills, coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and transdermal deposit band-aid) * Oral and written informed consent Exclusion Criteria: * Chemotherapy within 4 weeks * Radiotherapy within 4 weeks * Immunotherapy within 4 weeks * Other concomitant experimental treatment * Known neuropathy ≥ grade 2 * Serious congruous medical disease * Other previous malignant disease within 5 years, excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri * Previous serious and unexpected reactions to fluoropyrimidine treatment * Hypersensitivity to one or more of the active substances, auxiliary substances or fluoruracil * Patients with interstitial pneumonitis or pulmonary fibrosis